Clinical trials: Chronic Phase of Disease
Chronic Hepatitis B
A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults
This study is designed to assess the relative bioavailability of ABI-H2158 tablets (Test Formulation) compared to ABI-H2158 tablets (Reference Formulation).
- Trial name
- NCT04083716
- Testing
- ABI-H2158 Reference Formulation, ABI-H2158 Test Formulation
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Pulmonary Disease, Chronic Obstructive
Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.
This study will look at the pharmacokinetics, safety, toleration and efficacy of PF-00610355 in the chronic obstructive pulmonary disease (COPD) population.
- Trial name
- A7881010 (NCT00783406)
- Testing
- PF-00610355
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Pfizer
Secondary Hyperparathyroidism, Hemodialysis
Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism
This study is a exploratory comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in chronic kidney disease participants receiving hemodialysis with secondary hyperparathyroidism.
- Trial name
- NCT00990704
- Testing
- paricalcitol, maxacalcitol
- Where
- 14 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Abbott
Focal Segmental Glomerulosclerosis
Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5
This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with…
- Trial name
- NCT00816504
- Testing
- Galactose
- Where
- United States
- Sponsor
- Northwell Health
Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
The purpose of this trial is to evaluate safety and efficacy of surgical application of EB-101 (autologous, gene-corrected keratinocyte sheets) as a treatment of recessive dystrophic epidermolysis bullosa (RDEB).
- Trial name
- NCT04227106
- Testing
- EB-101
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Abeona Therapeutics, Inc
End Stage Renal Disease
Conventional Hemodialysis Vs Short Daily Hemodialysis for Patients Coming From Peritoneal Dialysis (HAPD/CAPD)
The purpose of this randomized study is to determine if the home SDHD is a suitable alternative to conventional dialysis performed in a dialysis center for patients suffering from chronic kidney disease from Peritoneal Dialysis…
- Trial name
- CHDvsSDHD (NCT02002949)
- Testing
- Short daily hemodialysis, Conventional hemodialysis
- Where
- 31 sites in Italy
- Volunteers
- 144 people
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
This is a Phase 1, open-label, multicenter study evaluating the safety and PK profile of ABT-199 under a once daily dosing schedule.
- Trial name
- NCT01328626
- Testing
- ABT-199
- Where
- 10 sites in United States, Australia
- Volunteers
- 222 people
- Sponsor
- AbbVie
Hepatic and Hepatobiliary Disorders
Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases
Primary Objective: To assess safety of Phosphatidylcholine paste 600 mg (ESSENTIALE® paste) oral 3 times a day for 12 weeks in patients with gastrointestinal symptoms in acute and chronic liver diseases.
- Trial name
- EPLID (NCT02517385)
- Testing
- Phosphatidylcholine
- Where
- Russia
- Volunteers
- 147 people
- Sponsor
- Sanofi
Transient Hypothyroxinemia of Prematurity (THOP)
Study of Thyroid Hormones in Prematures
The investigators hypothesize that continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days from birth will reduce by 30% or more (from an estimated 30% to 21%) the proportion of extremely…
- Trial name
- THOP2 (NCT02103998)
- Testing
- thryoid hormone T4 + oral potassium iodide (KI) for 42 days, D5W - 5% dextrose water
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- New York Medical College
Chronic Myeloid Leukemia
Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)
This is a phase II multicenter, open-label study designed to investigate the feasibility (tolerance, compliance and safety) of a combination of the tyrosine kinase inhibitor STI 571 (GLIVEC, Novartis Pharma) with a pegylated…
- Trial name
- NCT00511121
- Testing
- STI571 and PEG INTRON
- Volunteers
- 5 people
- Sponsor
- University of Bologna
Leukemia
Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00110058
- Testing
- recombinant interferon alfa, therapeutic allogeneic lymphocytes, cyclosporine
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
X-Linked Chronic Granulomatous Disease
Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD)
X-linked chronic granulomatous disease (X-CGD) is a rare genetic disorder, which affects boys. It is caused by an error in a gene that makes part of the immune system.
- Trial name
- CGD (NCT01855685)
- Testing
- X vivo gene therapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 3 people
- Sponsor
- Genethon
Cardiovascular Disease, Chronic Kidney Failure
Effect of HCO1100 on Cardiovascular Function
The purpose of this study is to determine whether high porous membranes are effective in the treatment of cardiovascular events in chronic dialysis patients.
- Trial name
- HicoCARD (NCT01363921)
- Testing
- HCO 1100
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Vantive Health LLC
HCV Infection
Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)
The purpose of this study is to assess the pharmacokinetics (PK), safety, and efficacy of oral MK-5172 (a fixed dose combination [FDC] tablet containing elbasvir [EBR] 50 mg and grazoprevir [GZR] 100 mg) and EBR/GZR (varying…
- Trial name
- NCT03379506
- Testing
- EBR/GZR FDC Tablet, Grazoprevir Oral Granules, Elbasvir Oral Granules
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 57 people
- Sponsor
- Merck Sharp & Dohme LLC
CML (Chronic Myelogenous Leukemia
IIT PH1 KDS-1001 in Patients With CML
This open label, non-randomized, prospective phase I study is designed to evaluate if the addition of natural killer cell therapy (KDS-1001) to tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) patients with…
- Trial name
- NCT04808115
- Testing
- KDS-1001
- Sponsor
- Duke University
Pulmonary Disease, Chronic Obstructive
Ba253BINEB in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to investigate the long-term safety of Ba253BINEB. Secondarily the long-term efficacy of Ba253BINEB is also investigated.
- Trial name
- NCT02182635
- Testing
- Ba253BINEB
- Volunteers
- 74 people
- Sponsor
- Boehringer Ingelheim
Chronic Phase Chronic Myeloid Leukemia
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
This study proposes to evaluate the number of chronic, Grade 1 or 2, non-hematologic Adverse Events (AEs) that reduce in grade or resolve at 3 months after switching therapy from imatinib to dasatinib.
- Trial name
- NCT01660906
- Testing
- Dasatinib
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF)
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
Objectives of this clinical trial are to evaluate the safety, tolerability, pharmacokinetics and potential efficacy of the investigational drug, cobomarsen (MRG-106), in patients diagnosed with certain lymphomas and leukemias…
- Conditions
- Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype
- Trial name
- NCT02580552
- Testing
- Cobomarsen
- Where
- 19 sites in United States
- Volunteers
- 66 people
- Sponsor
- miRagen Therapeutics, Inc.
HCV Infection
Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection
The purpose of this study is to determine whether a 3-day course of therapy with orally administered VCH-916 given at different dosages can effectively reduce the amount of circulating virus (i.e., viral load) in patients with…
- Trial name
- NCT00623649
- Testing
- VCH 916
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 42 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Growth Hormone Deficiency
National Cooperative Growth Study in CKD
The purpose of this study is to learn whether growth hormone being administered to children with Chronic Kidney Disease is effective and if it has any side effects.
- Trial name
- NCGS (NCT00616278)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Davis